Éric Raymond

29.6k total citations · 11 hit papers
369 papers, 22.4k citations indexed

About

Éric Raymond is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Éric Raymond has authored 369 papers receiving a total of 22.4k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Oncology, 159 papers in Molecular Biology and 87 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Éric Raymond's work include Pancreatic and Hepatic Oncology Research (56 papers), Cancer Treatment and Pharmacology (52 papers) and Neuroendocrine Tumor Research Advances (49 papers). Éric Raymond is often cited by papers focused on Pancreatic and Hepatic Oncology Research (56 papers), Cancer Treatment and Pharmacology (52 papers) and Neuroendocrine Tumor Research Advances (49 papers). Éric Raymond collaborates with scholars based in France, United States and Italy. Éric Raymond's co-authors include Sandrine Faivre, Esteban Cvitkovic, Stephen G. Chaney, Guido Kroemer, Jan M. Woynarowski, Annemilaï Tijeras‐Raballand, Armand de Gramont, Cindy Neuzillet, Christophe Le Tourneau and Maria Serova and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Accounts of Chemical Research.

In The Last Decade

Éric Raymond

363 papers receiving 21.9k citations

Hit Papers

Sunitinib Malate for the Treatment of Pancreat... 1998 2026 2007 2016 2011 2012 2005 2006 2002 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
    2011 1.8k citations Éric Raymond, Jean‐Luc Raoul et al. profile →
  2. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
    2012 1.2k citations Éric Raymond et al. profile →
  3. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
    2005 934 citations Sandrine Faivre, Giorgio Massimini et al. profile →
  4. Current development of mTOR inhibitors as anticancer agents
    2006 778 citations Sandrine Faivre, Éric Raymond et al. profile →
  5. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
    2002 683 citations Éric Raymond et al. profile →
  6. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
    2013 586 citations Éric Raymond et al. profile →
  7. Molecular basis for sunitinib efficacy and future clinical development
    2007 546 citations Sandrine Faivre, Éric Raymond et al. profile →
  8. Oxaliplatin: A review of preclinical and clinical studies
    1998 527 citations Éric Raymond, Esteban Cvitkovic et al. Annals of Oncology profile →
  9. mTOR-targeted therapy of cancer with rapamycin derivatives
    2005 520 citations Sandrine Faivre, Éric Raymond et al. Annals of Oncology profile →
  10. Targeting the TGFβ pathway for cancer therapy
    2014 489 citations Sandrine Faivre, Éric Raymond et al. profile →
  11. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
    2016 403 citations Rocio García‐Carbonero, Halfdan Sørbye et al. Neuroendocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Raymond France 71 10.9k 8.8k 4.6k 4.4k 3.1k 369 22.4k
Asif Rashid United States 70 9.7k 0.9× 4.8k 0.5× 4.3k 0.9× 7.0k 1.6× 1.4k 0.5× 305 20.3k
Jordan Berlin United States 60 15.3k 1.4× 6.6k 0.7× 6.3k 1.4× 2.0k 0.5× 2.8k 0.9× 357 22.9k
Takuji Okusaka Japan 65 10.7k 1.0× 3.4k 0.4× 4.7k 1.0× 5.3k 1.2× 5.4k 1.8× 534 19.6k
Filippo de Braud Italy 74 17.9k 1.6× 5.7k 0.6× 8.8k 1.9× 2.5k 0.6× 2.5k 0.8× 754 26.7k
Alan P. Venook United States 67 9.8k 0.9× 3.1k 0.4× 3.8k 0.8× 3.5k 0.8× 5.2k 1.7× 365 17.5k
Emilio Bajetta Italy 55 10.4k 1.0× 3.9k 0.4× 5.8k 1.3× 2.4k 0.6× 948 0.3× 325 16.6k
Sandrine Faivre France 58 6.8k 0.6× 6.7k 0.8× 3.4k 0.7× 1.6k 0.4× 1.6k 0.5× 286 14.9k
Ravi Salgia United States 90 10.6k 1.0× 12.5k 1.4× 8.4k 1.8× 1.7k 0.4× 3.2k 1.0× 626 27.5k
Allan T. van Oosterom Belgium 32 9.3k 0.9× 4.5k 0.5× 10.1k 2.2× 1.6k 0.4× 1.9k 0.6× 89 21.9k
Ann‐Lii Cheng Taiwan 80 10.4k 1.0× 7.9k 0.9× 4.8k 1.1× 5.1k 1.2× 10.1k 3.3× 794 28.2k

Countries citing papers authored by Éric Raymond

Since Specialization
Citations

This map shows the geographic impact of Éric Raymond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Raymond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Raymond more than expected).

Fields of papers citing papers by Éric Raymond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Raymond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Raymond. The network helps show where Éric Raymond may publish in the future.

Co-authorship network of co-authors of Éric Raymond

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Raymond. A scholar is included among the top collaborators of Éric Raymond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Raymond. Éric Raymond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bestion, Eloïne, Éric Raymond, Soraya Mezouar, & Philippe Halfon. (2023). Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors. Cells. 12(13). 1702–1702. 12 indexed citations
2.
Harding, James J., Ahmad Awada, Gaël S. Roth, et al.. (2022). First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. Liver Cancer. 11(3). 268–277. 16 indexed citations
3.
Hicks, Rodney J., Clarisse Dromain, Wouter W. de Herder, et al.. (2021). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology. 34(3). e13040–e13040. 13 indexed citations
4.
Raymond, Éric, Catherine Thiéblemont, S. Alran, & Sandrine Faivre. (2020). Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. Targeted Oncology. 15(3). 249–259. 93 indexed citations
5.
Delord, Jean‐Pierre, Antoîne Italiano, Ahmad Awada, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology. 16(1). 37–46. 8 indexed citations
6.
Lebbé, Célèste, Antoîne Italiano, Nadine Houédé, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology. 16(1). 47–57. 10 indexed citations
7.
García‐Carbonero, Rocio, Halfdan Sørbye, Éric Baudin, et al.. (2016). ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 103(2). 186–194. 403 indexed citations breakdown →
8.
Théry, Jean‐Christophe, Jean‐Philippe Spano, D. Azria, Éric Raymond, & F. Penault Llorca. (2014). Resistance to human epidermal growth factor receptor type 2-targeted therapies. European Journal of Cancer. 50(5). 892–901. 45 indexed citations
9.
Raymond, Éric, Angus Dalgleish, J.‐E. Damber, Matthew R. Smith, & Роберто Пили. (2013). Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemotherapy and Pharmacology. 73(1). 1–8. 63 indexed citations
10.
Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations
11.
Hammel, Pascal, Daniel Castellano, Eric Van Cutsem, et al.. (2011). Evaluation of Progression-Free Survival by Blinded Independent Central Review in Patients With Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors Treated With Sunitinib or Placebo. Pancreas. 40(2). 327–327. 2 indexed citations
12.
Lovejoy, Katherine S., Maria Serova, Ivan Bièche, et al.. (2011). ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS. Europe PMC (PubMed Central). 71 indexed citations
13.
Guillamo, Jean‐Sébastien, Sophie de Boüard, Samuel Valable, et al.. (2009). Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma. Clinical Cancer Research. 15(11). 3697–3704. 57 indexed citations
14.
Ghoul, Aïda, Maria Serova, Lucile Astorgues‐Xerri, et al.. (2009). Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells. Cancer Research. 69(10). 4260–4269. 44 indexed citations
15.
Raymond, Éric, Ivan Borbath, Jean‐Luc Raoul, et al.. (2009). Phase III, Randomized, Double-blind Trial of Sunitinib Versus Placebo in Patients With Progressive, Well-differentiated Pancreatic Islet Cell Tumours. Annals of Oncology. 20. 11–11. 7 indexed citations
16.
Raymond, Éric, Svein Dueland, Michael Lind, et al.. (2005). Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules. Cancer Research. 65. 936–936. 2 indexed citations
17.
Hasbini, Ali, Éric Raymond, Esteban Cvitkovic, François Eschwège, & Jean‐Pierre Armand. (2000). Les carcinomes du nasopharynx. Bulletin du Cancer. 87(12). 21–26. 2 indexed citations
18.
Raymond, Éric, et al.. (2000). DNA G-Quadruplexes, Telomere-Specific Proteins and Telomere-Associated Enzymes as Potential Targets for New Anticancer Drugs. Investigational New Drugs. 18(2). 123–137. 28 indexed citations
19.
Raymond, Éric, Siham Djelloul, Christine Buquet-Fagot, Ján Mešter, & Christian Gespach. (1996). Synergy between the non-classical thymidylate synthase inhibitor AG337 (ThymitaqR) and cisplatin in human colon and ovarian cancer cells. Anti-Cancer Drugs. 7(7). 752–757. 13 indexed citations
20.
Piccart, Martine, Éric Raymond, Matti Aapro, Elizabeth A. Eisenhauer, & Esteban Cvitkovic. (1995). Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: Current status and future prospects. European Journal of Cancer. 31. S1–S10. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Asif Rashid Breakdown of academic impact, for papers by Jordan Berlin Breakdown of academic impact, for papers by Takuji Okusaka Breakdown of academic impact, for papers by Filippo de Braud Breakdown of academic impact, for papers by Alan P. Venook Breakdown of academic impact, for papers by Emilio Bajetta Breakdown of academic impact, for papers by Sandrine Faivre Breakdown of academic impact, for papers by Ravi Salgia Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by Ann‐Lii Cheng
Rankless by CCL
2026